Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer
Publication date
2015-09-01
Authors
Braam, H. J.
Schellens, Jan H M
Boot, H.
van Sandick, J. W.
Knibbe, C. A.
Boerma, D.
van Ramshorst, B.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Purpose: Several studies have shown the potential benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients. At present the most effective chemotherapeutic regime in HIPEC for gastric cancer is unknown. The aim of this review was to provide a comprehensive overview of chemotherapeutic agents used for HIPEC in gastric cancer. Methods: A literature search was conducted using the PubMed database to identify studies on chemotherapy used for HIPEC in gastric cancer patients. Results and conclusion: The chemotherapeutic regime of choice in HIPEC for gastric cancer has yet to be determined. The wide variety in studies and study parameters, such as chemotherapeutic agents, dosage, patient characteristics, temperature of perfusate, duration of perfusion, carrier solutions, intraperitoneal pressure and open or closed perfusion techniques, warrant more experimental and clinical studies to determine the optimal treatment schedule. A combination of drugs probably results in a more effective treatment.
Keywords
Chemotherapy, Hyperthermia, Intraoperative period, Intraperitoneal, Metastasis, Peritoneal neoplasms, Pharmacokinetics, Stomach neoplasms, Taverne, Oncology, Hematology, Geriatrics and Gerontology, SDG 3 - Good Health and Well-being
Citation
Braam, H J, Schellens, J H, Boot, H, van Sandick, J W, Knibbe, C A, Boerma, D & van Ramshorst, B 2015, 'Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer', Critical Reviews in Oncology Hematology, vol. 95, no. 3, pp. 282-296. https://doi.org/10.1016/j.critrevonc.2015.04.004